Member Info for Brighty1

I'm with you Aberystwyth, a comment from Chairman Parker with that Re-Tweet would have much more impact than just a straight forward re-tweet. He doesn't need to clear it with the Nomad or Citigate, he can just add what's already been OK'd from a previous RNS as a foot note. This is straight forward stuff. Hope news is on the way. Brighty.

Whilst Q3/4 is the pivotal time frame that most long term holders of Sareum are waiting for it would still have been good for SAR to go in to this forthcoming period with a head of steam at 1p - 1.5p or above not 0.75 or below. It's not "ramping", to coin a phrase, its good management. Most savvy plc's understand that a comms strategy is part and parcel of the equation to stabilise and maintain a share price ahead of news. I know from your posts, Elcap, that you get this but I do worry that others are not grasping the basic point that Sareum are missing the basic building blocks to take the share price up prior to news. If this is not addressed we all lose out. Brighty

Until SAR start proactively communicating with and to the investor community the SP will continue to drift. I am also staggered that the Lupus news appeared on this forum first. We all know that SAR is potentially sitting on a "goldmine of news". However, they are going to have to be much much better at their comms if we are to all benefit from the "best in class" science and enjoy the "significant share holder value" alluded to by SAR's CEO and Chairman. Brighty

The buying yesterday was pretty intense so we should have another good day today. Good luck all. 20p+ in the next few weeks. Brighty

This is a superb RNS in the current circumstances. Looking good moving forward. Bring on 2021 and 100p minimum. Brighty

Better than expected results today. Markets division performed strongly. Brighty

The summary from Next today regarding its online performance bodes well for BWNG, see below. Good news all. Brighty.
NEXT
In summary, the Company is in a much better position than we anticipated three months ago: consumer demand has held up better than expected and our Online warehouses have achieved much higher capacities than we thought possible. Costs have been well controlled, and we have taken steps to ensure that our balance sheet is secure.

Whilst much of our time has been focussed on managing the business through the pandemic, we have not lost sight of the fact our sector was already experiencing far-reaching structural changes as consumers increase their expenditure Online. If anything, these changes are likely to accelerate as a result of the crisis. So, we have continued to move the business forward, actively investing in the systems, Online capacity and business ideas that we believe will be important in a post pandemic world.

Without Citizen's post last week on this forum we might not have even had the RNS yet. The proactive messaging is still non existent and the slide in the SP is nothing new. Until Sareum master the art of communication with share holders this will be the result time after time. Brighty

Baserite, spot on. I nearly spat my coffee out when I read LTH's will be selling or slicing soon! I'm in for M&A / licencing activity much further down the line. I.e. Thoth's 28p is where I think Sar is heading and hopefully much higher. Good luck long term holders. I lam here for the big gains. Brighty

RMM, it would certainly help if Sareum communicated these significant financial numbers in a footnote in their RNS announcements. Many other pharmas talk about global market values. I would like to see this more from Sareum. It would help the investor community focus on the magnitude of what could be achieved. i.e. let the numbers do the talking. Brighty

12 months ago we had an out of the blue VCSEL Production Update on 24th July which took the share price up from 50 to 62p. With the recent Skyworks announcement, which was clearly very good news for IQE, and the AMS update tomorrow the stars are starting to align for a favouarble second half to 2020. I'm hoping for another positive un-scheduled update in the next few days. AMS should be very positive tomorrow which bodes well for IQE moving forward on the back of Skyworks. Good luck, Brighty

Here's to the newly merged company and a share price pre the q4 drill of 8-10p+. Therefater, lets be the new TXP. Brighty.

With Astra's multi billion Daiichi Sankyo deal today it shows you the potential of companies like N4P being in the right place at the right time. Fingers crossed. It's been a long time coming but maybe things are starting to look brigther here. Brighty

Yes, it says AZ will pay an upfront payment to Daiichi Sankyo of $1bn plus additional amounts of up to $1bn for the successful achievement of regulatory approvals and up to, wait for it, a staggering $4bn for sales-related milestones. Just shows you the ££s SNG could be looking at. Brighty

The AstraZeneca Daiichi Sankyo multi £billion deal today just goes to show us all what could be on the table for the likes of Synairgen and Sareum. Right place at the right time. Good luck all, Brighty

The AstraZeneca Daiichi Sankyo multi £billion deal today just goes to show us all what could be on the table for the likes of Sareum and Synairgen. Right place at the right time. Good luck all, Brighty

Pleasantly surprised to see this rise so much today (40% so far) but as we all know here Webis is a multi bag investment opportunity. Re an acquisition BarnetPeter, who knows, but this is what Webis said recently in an RNS:

"As a result, the company has had no shortage of informal offers from other interested parties in the space, specifically in the areas of software deals, strategic alliances and, at the operating company level only, mergers and even acquisition"….

Hence why I am a long term shareholder in Webis. Here's to a great outcome whether it is M&A or sports betting in California. which will see this multi bag significantly. Brighty

To maintain momentum Sareum should now communicate proactively to the investor community and health and science media their data related to Covid 19 and the Sareum TYK2/JAK1 inhibitor candidates, – SDC-1801 and SDC-1802 and the significant potential Sareum's science has in treating respiratory symptoms such as advanced COVID-19 as well as other autoimmune diseases. As many people have stated on this board over the years and more recently, regarding Covid 19, Sareum is sitting on a goldmine of data and information which if communicated proactively will send the share price soaring. The next announcement could therefore be a very big one indeed. i.e. a joint venture with a licencing partner or M&A. Remember, Sareum have already stated that they will be making applications for grant funding to investigate the potential of their TYK2/JAK1 in COVID-19. When SAR release confirmation of the grant this should have a significant impact as well. So, for all SAR newbies this is a hold rather than a quick sell in my opinion as we are looking at a share price that could be multiples of where it is now. See SNG, ODX, AVCT, HEMO, NCYT, PYC, YGEN, all of which I hold, for pharma stocks in the right place at the right time. SAR is also in this space and in the right place at exactly the opportune moment. They just need to communicate what they have. Dyor and good luck, Brighty

Broken 1p. Good start. Brighty

Fingers crossed everyone. At last we have some news from SAR. Interesting point re Lupus + Covid19. Should see us stabalise at least at 1p or maybe even 1.5p today in readiness for the next bigger news to come. Brighty.